Home/Pipeline/COPD Phenotyping & Progression Biomarkers

COPD Phenotyping & Progression Biomarkers

Chronic Obstructive Pulmonary Disease (COPD)

Commercial/ValidationActive

Key Facts

Indication

Chronic Obstructive Pulmonary Disease (COPD)

Phase

Commercial/Validation

Status

Active

Company

Thirona

About Thirona

Thirona is a leader in AI-driven lung image analysis, leveraging over two decades of research to transform subjective CT scan interpretation into objective, quantitative data. Its core LungQ platform is extensively validated and used globally by hospitals and pharmaceutical companies to characterize complex respiratory diseases like COPD, severe asthma, and cystic fibrosis. The company operates a B2B platform and services model, generating revenue by accelerating clinical trials and enabling precision pulmonary interventions.

View full company profile

Therapeutic Areas

COPD Severe Asthma Cystic Fibrosis Bronchiectasis Emphysema

Other Chronic Obstructive Pulmonary Disease (COPD) Drugs

Drug	Company	Phase	Status
PUR0200	Pulmatrix	Preclinical	Active
COPD Trial	Well Pharma Medical Research	Not Specified	Active
AN01	AirNexis Therapeutics	Phase 2	Active
COPD Diagnostic/Prognostic Test	Oxford Cancer Analytics	Pre-clinical	Active
SMS Cell Therapy	SMSbiotech	Phase 1b	Active
dNerva Lung Denervation System / Targeted Lung Denervation (TLD)	Nuvaira	Phase 3	Active
LBP for COPD	Alveolus Bio	Preclinical	Active
AstraZeneca Collaboration Programs	Ethris	Discovery/Pre-clinical	Active
TEZSPIRE (tezepelumab)	Amgen	Phase 3	Active
Dupixent (Dupilumab)	Sanofi	Phase 3	Active
Verekitug (UPB-101)	Upstream Bio	Phase 2	Ongoing